Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
about
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Effects of tobacco smoking and nicotine on cancer treatment.Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursModel-based treatment optimization of a novel VEGFR inhibitor.Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid TumoursClinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour.Therapeutic drug monitoring for imatinib: Current status and Indian experience.Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?The role of imatinib plasma level testing in gastrointestinal stromal tumor.Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Therapeutic drug monitoring of targeted anticancer therapy.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor.An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.Accomplishments in 2008 in the management of gastrointestinal stromal tumors.Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.Activity-based kinase profiling of approved tyrosine kinase inhibitors.Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.Imatinib plasma levels: correlation with clinical benefit in GIST patients.Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.Toward personalized, targeted therapy of gastrointestinal stromal tumor.Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes.Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
P2860
Q33427392-509C7098-77F3-4A8D-A0A5-5E3D8497FFA7Q33921067-59AC88FE-613B-4331-8F1A-72118AA67F87Q34303604-5B0C8FEB-DFFC-4C8E-8E76-79C67E8F3CD0Q34377463-5B9AEE80-C283-4019-A502-7B09E8BA2171Q34417423-35C186D7-0878-4005-AE20-DBE5B93D95F7Q36729934-CA63551D-43CA-40C9-B92F-9908020A6B6EQ36779136-8B14B725-F12A-4D92-9D0E-9C4698E98534Q37000818-4B95C3DD-E13E-4588-97C9-2E2B01D116DCQ37504935-3A3968E9-8A62-48EA-A45F-FD270AF76DD7Q37517632-4D504A13-6979-430B-88F7-2D790CF2F120Q37729245-589964FA-1486-4B48-9374-74A79E03CFD8Q37731289-86ED8A16-5B55-40CE-8D40-3014CF006367Q37817815-66092ADA-A600-4C0E-8DDF-DF01C0BD5269Q37823438-D9FA33D7-5487-4802-B7EE-1313DA623D16Q37862942-CAFE9ECD-0434-4BF8-80EE-6C0A97DC2F82Q38112821-C5A7B2F4-5285-4650-8A7C-4EA1A0ACEF0AQ38579278-1BFB485F-CFC5-4A00-92BD-93C83398D54DQ38937228-74840349-5D99-42D7-A137-BB80E5F5ED43Q38995804-5E10DDB6-8147-4102-AD30-322702516C52Q39118167-330BBD04-5315-47D0-A30C-76D469AD0A55Q39651800-4F1CE8A2-62D9-4247-B0BD-9A16F7683092Q40213114-FBE08FE1-F694-4687-8F75-65788A11B7D8Q42287336-DA7D7586-6C77-476E-97FB-092F723C0EDAQ42556614-D02888E8-233A-400C-8068-BE10FEFC8ED0Q42713576-023D66B9-0105-4C00-B39F-65A8815EA359Q42723108-4F445880-A5C3-4E95-B244-914214F26D87Q42843116-C16404DD-F176-4507-B0E0-A1108CCA3BD9Q42845531-BD1B2BE6-D473-4DA6-A705-56517429B418Q43191940-97114D66-3C6B-458F-BDB3-09D8795D67EDQ47847397-10A49AA0-7423-4408-98C2-A46D6AD6A0BDQ48278939-20CE6B02-CE83-46E3-9A4E-18594E4D3F63Q53173883-8356ED9F-4521-4632-BB8D-D9A27344DC83Q54323723-C9798C92-AA46-4025-BA57-7784D5686D05Q54485945-332C6D69-FDF1-4773-A5F3-56E77F7197EDQ55070104-BBEC7512-750A-4793-84AD-2B6AAEF0B969
P2860
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Relationship of imatinib-free ...... ith efficacy and tolerability.
@ast
Relationship of imatinib-free ...... ith efficacy and tolerability.
@en
type
label
Relationship of imatinib-free ...... ith efficacy and tolerability.
@ast
Relationship of imatinib-free ...... ith efficacy and tolerability.
@en
prefLabel
Relationship of imatinib-free ...... ith efficacy and tolerability.
@ast
Relationship of imatinib-free ...... ith efficacy and tolerability.
@en
P2093
P2860
P50
P356
P1476
Relationship of imatinib-free ...... ith efficacy and tolerability.
@en
P2093
A Rosselet
L A Decosterd
M A Duchosal
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604355
P407
P577
2008-05-06T00:00:00Z